HERSHEY, Pa., and ROCKVILLE, Md., March 25, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc., ("ITI") a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces it has concluded pre-IND discussions with the U.S. Food and Drug Administration regarding its proprietary ARA-LAMP-Vax vaccine currently under development for peanut allergies. The company received positive and helpful feedback, which it expects will be instrumental in designing its Phase 1 trials.
"Our meeting with the FDA proved illuminating and extremely helpful," said William Hearl, Ph.D., CEO of ITI. "Based on the feedback we received, we anticipate moving forward with our Phase 1 trials for our proprietary peanut allergy vaccine soon. We are grateful for the feedback, and look forward to continued collaboration with the Agency."
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a Hershey, PA-based, privately held, clinical stage biotechnology company developing vaccines based on the LAMP technology platform, which was exclusively licensed from Johns Hopkins University. The LAMP-vax vaccine platform aims to increase the immune response to nucleic acid vaccines and simplify vaccine design and delivery for safer, more cost-effective therapies. ITI's LAMP constructs have been validated in human clinical trials for cancer and have been studied in areas including allergy and infectious disease, while internally ITI is focused on developing allergy therapies. Currently, the company is pursuing three main allergy programs:
- ASP 4070 (Formerly known as JRC-LAMP-Vax) - Japanese Red Cedar Vaccine - An innovative potential solution for the over 35 million sufferers of Japanese red cedar pollinosis - Phase I, currently partnered with Astellas Pharma;
- An analogous vaccine formulation will be developed as a vaccine to treat Mountain Cedar in the US.
- ARA-LAMP-Vax Peanut Allergy Vaccine - A therapeutic vaccine in development, with a goal of mitigating peanut allergy - Beginning Phase I in late 2015/early 2016;
- Multi Allergen Vaccines (Product Concepts) - Allergy vaccine formulation concepts that would aim to address the major categories of allergies of concern Worldwide - Under study & development.
For more information about ITI and LAMP Technology, please visit www.immunomix.com.
CONTACT: Jules Abraham JQA Partners, Inc. firstname.lastname@example.org (917) 885-7378 Sia Anagnostou Immunomic Therapeutics, Inc email@example.com http://www.immunomix.com (717) 327-1822Source:Immunomic Therapeutics, Inc.